StreetInsider.com News Articles

Form 4 CAPRICOR THERAPEUTICS, For: May 26 Filed by: Maurer Michael T

Thu, 28 May 2026 21:55:00 -0400

si-local-file:///var/storage/secattach/20260528/26569516.html

Form 4 CAPRICOR THERAPEUTICS, For: May 26 Filed by: Maurer Michael T

Thu, 28 May 2026 21:55:00 -0400

si-local-file:///var/storage/secattach/20260528/26569516.html

Form 3 CAPRICOR THERAPEUTICS, For: May 25 Filed by: Maurer Michael T

Thu, 28 May 2026 21:52:00 -0400

si-local-file:///var/storage/secattach/20260528/26569514.html

Form 3 CAPRICOR THERAPEUTICS, For: May 25 Filed by: Maurer Michael T

Thu, 28 May 2026 21:52:00 -0400

si-local-file:///var/storage/secattach/20260528/26569514.html

Form 4 CAPRICOR THERAPEUTICS, For: May 18 Filed by: Bergmann Anthony

Tue, 19 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260519/26521331.html

Form 4 CAPRICOR THERAPEUTICS, For: May 18 Filed by: Bergmann Anthony

Tue, 19 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260519/26521331.html

Form 144/A CAPRICOR THERAPEUTICS, Filed by: Musket David B

Tue, 19 May 2026 14:41:00 -0400

si-local-file:///var/storage/secattach/20260519/26520468.html

Form 144/A CAPRICOR THERAPEUTICS, Filed by: Musket David B

Tue, 19 May 2026 14:41:00 -0400

si-local-file:///var/storage/secattach/20260519/26520468.html

Form 144 CAPRICOR THERAPEUTICS, Filed by: Musket David B

Tue, 19 May 2026 11:40:00 -0400

si-local-file:///var/storage/secattach/20260519/26519567.html

Form 144 CAPRICOR THERAPEUTICS, Filed by: Musket David B

Tue, 19 May 2026 11:40:00 -0400

si-local-file:///var/storage/secattach/20260519/26519567.html

Form 4 CAPRICOR THERAPEUTICS, For: May 13 Filed by: Litvack Frank

Thu, 14 May 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260514/26496358.html

Form 4 CAPRICOR THERAPEUTICS, For: May 13 Filed by: Litvack Frank

Thu, 14 May 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260514/26496358.html

Form 10-Q CAPRICOR THERAPEUTICS, For: Mar 31

Wed, 13 May 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260513/26487599.html

Form 10-Q CAPRICOR THERAPEUTICS, For: Mar 31

Wed, 13 May 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260513/26487599.html

B.Riley Reiterates Buy Rating on Capricor Therapeutics (CAPR)

Wed, 13 May 2026 04:15:11 -0400

B.Riley analyst Madison El-Saadi reiterated a Buy rating and $63.00 price target on Capricor Therapeutics (NASDAQ: CAPR).

The analyst comments "We're reiterating our Buy rating and $63 PT on CAPR following 1Q26 results, with incremental disclosures across legal, regulatory, and commercial workstreams that we believe materially improve the asymmetric setup into the 8/22/26 PDUFA. Despite 435% 6M gain (vs. XBI 20%), we believe shares remain attractive given Deramiocel should have multiple paths to multi-billion peak revenue; we view the ~10% sell-off (^RUT -2%) following the 5/7 disclosure of CAPR's rescission filing against Nippon Shinyaku and NS Pharma as an opportunity, given

Capricor Therapeutics (CAPR) Misses Q1 EPS by 7c

Tue, 12 May 2026 16:13:44 -0400

Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.59), $0.07 worse than the analyst estimate of ($0.52).

Guidance

Financial Outlook: The Company believes that, based on the current operating plan and financial resources, its available cash, cash equivalents and marketable securities will be sufficient to cover anticipated expenses and capital requirements through Q4 2027. This outlook excludes any potential revenue from product sales, the potential monetization of a PRV, if received, or other non-operating sources of capital.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

Capricor Therapeutics (CAPR) Misses Q1 EPS by 7c

Tue, 12 May 2026 16:13:44 -0400

Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.59), $0.07 worse than the analyst estimate of ($0.52).

Guidance

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

Form 8-K CAPRICOR THERAPEUTICS, For: May 12

Tue, 12 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260512/26477766.html

Form 8-K CAPRICOR THERAPEUTICS, For: May 12

Tue, 12 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260512/26477766.html

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 16:05:00 -0400

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon
HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all Type I error-controlled secondary endpoints
GMP manufacturing facility fully operational; second-floor expansion well underway
Chief Commercial Officer with direct DMD commercial experience expected to join the Company in the coming weeks
Filed suit against Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. seeking rescission of U.S. distribution agreement and preliminary injunction; FDA review and PDUFA date unaffected
Cash balance of approximately $279

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 16:05:00 -0400

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon
HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all Type I error-controlled secondary endpoints
GMP manufacturing facility fully operational; second-floor expansion well underway
Chief Commercial Officer with direct DMD commercial experience expected to join the Company in the coming weeks
Filed suit against Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. seeking rescission of U.S. distribution agreement and preliminary injunction; FDA review and PDUFA date unaffected
Cash balance of approximately $279

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 16:05:00 -0400

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon
HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all Type I error-controlled secondary endpoints
GMP manufacturing facility fully operational; second-floor expansion well underway
Chief Commercial Officer with direct DMD commercial experience expected to join the Company in the coming weeks
Filed suit against Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. seeking rescission of U.S. distribution agreement and preliminary injunction; FDA review and PDUFA date unaffected
Cash balance of approximately $279

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 16:05:00 -0400

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon
HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all Type I error-controlled secondary endpoints
GMP manufacturing facility fully operational; second-floor expansion well underway
Chief Commercial Officer with direct DMD commercial experience expected to join the Company in the coming weeks
Filed suit against Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. seeking rescission of U.S. distribution agreement and preliminary injunction; FDA review and PDUFA date unaffected
Cash balance of approximately $279

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 16:05:00 -0400

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon
HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all Type I error-controlled secondary endpoints
GMP manufacturing facility fully operational; second-floor expansion well underway
Chief Commercial Officer with direct DMD commercial experience expected to join the Company in the coming weeks
Filed suit against Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. seeking rescission of U.S. distribution agreement and preliminary injunction; FDA review and PDUFA date unaffected
Cash balance of approximately $279

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 16:05:00 -0400

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon
HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all Type I error-controlled secondary endpoints
GMP manufacturing facility fully operational; second-floor expansion well underway
Chief Commercial Officer with direct DMD commercial experience expected to join the Company in the coming weeks
Filed suit against Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. seeking rescission of U.S. distribution agreement and preliminary injunction; FDA review and PDUFA date unaffected
Cash balance of approximately $279